Wells Fargo & Company Recursion Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 77,215 shares of RXRX stock, worth $512,707. This represents 0.0% of its overall portfolio holdings.

Number of Shares

77,215

Previous 58,517 31.95%

Holding current value

$512,707

Previous $583,000 0.69%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$7.35 - $10.05 $137,430 - $187,914	18,698 Added 31.95%	77,215 $579,000
Q1 2024 May 10, 2024	BUY	$9.13 - $15.52 $59,774 - $101,609	6,547 Added 12.6%	58,517 $583,000
Q4 2023 Feb 09, 2024	SELL	$5.09 - $10.79 $981,932 - $2.08 Million	-192,914 Reduced 78.78%	51,970 $512,000
Q3 2023 Nov 13, 2023	BUY	$6.59 - $15.86 $867,323 - $2.09 Million	131,612 Added 116.19%	244,884 $1.87 Million
Q2 2023 Aug 15, 2023	BUY	$4.56 - $9.94 $112,376 - $244,961	24,644 Added 27.81%	113,272 $846,000
Q1 2023 May 12, 2023	BUY	$6.42 - $9.64 $555,991 - $834,852	86,603 Added 4276.69%	88,628 $591,000
Q4 2022 Feb 13, 2023	BUY	$7.16 - $12.7 $2,155 - $3,822	301 Added 17.46%	2,025 $15,000
Q3 2022 Nov 14, 2022	BUY	$7.83 - $13.6 $2,646 - $4,596	338 Added 24.39%	1,724 $19,000
Q2 2022 Aug 12, 2022	SELL	$5.04 - $9.26 $43,636 - $80,173	-8,658 Reduced 86.2%	1,386 $12,000
Q1 2022 May 16, 2022	SELL	$6.16 - $18.03 $250,102 - $732,036	-40,601 Reduced 80.17%	10,044 $71,000
Q4 2021 Feb 14, 2022	BUY	$16.14 - $21.86 $817,200 - $1.11 Million	50,632 Added 389476.91%	50,645 $868,000
Q3 2021 Nov 15, 2021	BUY	$19.03 - $41.33 $247 - $537	13 New	13 $0

Others Institutions Holding RXRX

# of Institutions

291

Shares Held

241M

Call Options Held

984K

Put Options Held

2.4M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.2B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Recursion Pharmaceuticals, Inc. Transaction History